|
Synonyms: LR12
Compound class:
Peptide
Comment: Nangibotide (LR12) is a 12 amino-acid synthetic peptide that was designed as an inhibitor of TREM1 receptor-mediated pro-inflammatory signalling (e.g., release of IL-1β and IL-8) [7]. It is a fragment of the the soluble TREM-like transcript-1 (TLT-1) derivative LR17 [2]. Nangibotide is intended to reduce excessive inflammatory responses and reduce tissue damage. It is a useful experimental tool for further investigations into the potential of TREM1 inhibition for the treatment of acute and chronic noninfectious inflammatory disorders such as myocardial ischemia-reperfusion injury, septic shock, acute lung injury, osteoarthritis, and acute liver failure.
Nangibotide was the first TREM1 inhibitor to progress as a clinical candidate. |
| No information available. |
Summary of Clinical Use ![]() |
| A phase I first-in-man drug safety and pharmacokinetics study has been completed [1]. SARS-CoV-2: Nangibotide was evaluated in patients with COVID-19-related ARDS who were assessed as having TREM1 activation [3,6]. |
| Clinical Trials | |||||
| Clinical Trial ID | Title | Type | Source | Comment | References |
| NCT03158948 | Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of 3 Doses of MOTREM (Nangibotide) in Patients With Septic Shock | Phase 2 Interventional | Inotrem | 4 | |
| NCT03463044 | Safety, Tolerability and Pharmacokinetic Profiles of MOTREM (LR12) in Healthy Male Subjects | Phase 1 Interventional | Inotrem | ||
| NCT04429334 | Efficacy and Safety Study of Nangibotide in Patients With COVID-19 Receiving Ventilatory Support | Phase 2 Interventional | Inotrem | 3 | |
| NCT04055909 | Efficacy, Safety and Tolerability of Nangibotide in Patients With Septic Shock | Phase 2 Interventional | Inotrem | The ASTONISH study | 5 |